Net Income

Genmab discontinues its 'encouraging' lung cancer drug, acasunlimab, in a bold strategic pivot to accelerate its most promising late-stage assets.

In a move to protect shareholders, IP Strategy canceled a dilutive financing deal, signaling deep confidence in its $IP token reserves and the Story ecosystem.

A pivotal trial for an acute myeloid leukemia drug is delayed for a promising reason: patients are surviving longer than anticipated, fueling cautious optimism.

Israeli innovator Foresight gets a major nod from Audi, showcasing its all-weather 3D vision system that could redefine autonomous vehicle safety.

Fresh off a volatile IPO, Malaysian hotpot chain CCH Holdings plans a massive 2026 expansion. Can this small-cap company conquer the U.S. and Africa?

TRON founder Justin Sun injects $18M into Nasdaq-listed Tron Inc., bolstering its crypto treasury and cementing its unique dual business model.

A critical labor dispute at Canada’s largest propane export terminal is over, but not before testing the resilience of a key global energy supply chain.

As 374Water pushes its waste-destroying tech to market, a new board member with deep financial expertise and a history as a long-term investor joins.

The cleantech firm hits key milestones in German and Italian energy projects while its unconventional portfolio expands into biotech and agritech.

Azenta divests its medical refrigeration unit to streamline its portfolio, signaling a strategic pivot to its high-growth multiomics and sample management services.

With a promising schizophrenia drug stalled by FDA requirements and finances tight, Reviva Pharmaceuticals' upcoming presentation is more than just a talk.

After a 600%+ stock surge and an abrupt SEC trading halt, Charming Medical is now facing class action lawsuits alleging a social media manipulation scheme.

Chinese cloud firm Cloopen forms a special committee to eye a go-private deal from its own CEO, putting shareholder value and corporate governance in the spotlight.

Chinese firm launches durable centrifuges for sub-zero climates and announces a major localization strategy to capture a multi-billion dollar market.

iQSTEL caps a transformational year with a NASDAQ uplist, record revenue, and a strategic pivot to Fintech and Cybersecurity, eyeing a $1B future.

MySize Inc. projects a pivotal 2026 after a strategic overhaul, but a history of losses and a plummeting stock price fuel deep market skepticism.

Core AI divests its cash-burning Siyata Mobile hardware unit just months after merging, betting its future entirely on AI-powered gaming and content.

After a turbulent year, the sleep apnea device maker aims to prove its rocky product launch is behind it and convince investors of a strong 2026.

The specialty construction firm closes a major refinancing deal, slashing borrowing costs and unlocking capital for acquisitions and expansion.

After resolving a key manufacturing issue, Unicycive has resubmitted its kidney drug NDA, offering new hope for dialysis patients with a lower pill burden.